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The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
the treatment of hematological malignancies remains hampered by life-threatening
chronic graft vs. host disease (cGVHD). Although multifactorial in nature, cGVHD
has been associated with imbalances between effector and regulatory T cells (Treg).
To further elucidate this issue, we performed a prospective analysis of patients
undergoing unrelated donor allo-HSCT after a reduced intensity conditioning (RIC)
regimen containing anti-thymocyte globulin (ATG) and the same GVHD prophylaxis, at a
single institution. We studied T cell subset homeostasis over a 24-month follow-up after
HSCT in a comparative analysis of patients with and without cGVHD. We also quantified
naive and memory T cell subsets, proliferation and expression of the apoptosis-related
proteins Bcl-2 and CD95. Finally, we assessed thymic function by T cell receptor excision
circle (TREC) quantification and T cell receptor (TCR) diversity by TCRVβ spectratyping.
While the total number of conventional CD4 (Tcon) and CD8T cells was similar between
patient groups, Treg were decreased in cGVHD patients. Interestingly, we also observed
divergent patterns of Naive and Stem Cell Memory (SCM) subset recovery in Treg and
Tcon compared to CD8. Patients with cGVHD showed impaired recovery of Naive and
SCM Tcon and Treg, but significantly increased frequencies and absolute numbers of
Naive and SCM were observed in the CD8 pool. Markedly increased EMRA CD8T cells
were also noted in cGVHD. Taken together, these results suggest that Naive, SCM
and EMRA CD8 play a role in the emergence of cGHVD. Reduced Naive and recent
thymic emigrant Tcon and Treg in cGVHD was likely due to impaired thymic output, as
it was accompanied by decreased CD4 TREC and TCR diversity. On the other hand,
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CD8 TCR diversity was similar between patient groups. Furthermore, no correlation was
observed between CD8 TREC content and Naive CD8 numbers, suggesting limited
thymic production of Naive CD8T cells in patients after transplant, especially in those
developing cGVHD. The mechanisms behind the opposing patterns of CD4 and CD8
subset cell recovery in cGVHD remain elusive, but may be linked to thymic damage
associated with the conditioning regimen and/or acute GVHD.
Keywords: chronic graft vs. host disease, hematopoietic stem cell transplantation, T lymphocyte, stem cell
memory, Naive T cell, immune reconstitution
INTRODUCTION
Despite the recent advances with patient-tailored therapies,
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
has been increasingly used in the USA and in Europe for the
treatment of hematological malignancies (1, 2). However, this
technique is not without risks and is frequently accompanied by
serious complications such as graft vs. host disease (GVHD) and
infections, which are major causes of morbidity and mortality
post-transplant (3). GVHD results from the recognition of
patient tissues by donor-derived effector cells. Acute GVHD
(aGVHD) typically occurs early after transplant, has markedly
inflammatory manifestations and is thought to be primarily
mediated by mature T lymphocytes infused with the graft
(4). On the other hand, chronic GVHD (cGVHD) usually
occurs later after transplant and resembles an auto-immune
disease (5), affecting specific target organs, primarily the eyes,
mouth, gastrointestinal tract, liver, skin, lungs, musculoskeletal,
and genitourinary systems (6). Chronic GVHD has a complex
pathophysiology. Thymic damage resulting both from the
conditioning regimen and acute GVHD likely has an impact on
normal T cell development (7, 8), and self-reactive T cells are
believed to play a pivotal role in the development of cGVHD.
Moreover, there appears to be a deficit in the regulatory T
cell pool, contributing to the loss of immunologic tolerance
post-transplant. A pivotal role for autoreactive B cells and
the production of self-reactive antibodies has also been clearly
associated to cGVHD pathogenesis, whereby self-reactive B
lymphocytes are activated due to increased levels of BAFF (9, 10).
In the end, excessive macrophage activation leads to fibroblast
proliferation and collagen deposition, which is a hallmark of
cGVHD (11).
The imbalances in regulatory (Treg) and effector T cells
(12) appear to be central to cGVHD pathogenesis. This has
led to clinical trials investigating the effect of low-dose rhIL-
2 in patients with cGVHD in order to induce Treg expansion
in vivo (13, 14). Also with the aim of increasing the Treg
pool, we and others are conducting clinical trials of donor
Abbreviations: aGVHD, acute GVHD; ALL, acute lymphoid leukemia; AML,
acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic
myeloid leukemia; cGVHD, chronic GVHD; CMV, cytomegalovirus; F, female; G,
grade; GVHD, Graft versus Host Disease; HL, Hodgkin lymphoma; HLA, human
leukocyte antigen; M, male; MDS, myelodysplastic syndrome; MF, Myelofibrosis;
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood
stem cell.
Treg infusion in patients with moderate and severe cGVHD
(www.tregeneration.eu).
The involvement of donor T cells in the pathophysiology
of GVHD led to the development of ex vivo (T cell-depleted
grafts) and in vivo (anti-thymocyte globulin; ATG) T cell
depletion approaches that significantly reduce GVHD incidence
(5). ATG also delays immune reconstitution post-transplant
through the depletion and/or function modification of T,
B and NK cells (15). However, ATG does not completely
abrogate the emergence of cGVHD (16–18), which attests
to the multifactorial nature of this condition. On the other
hand, thymic ablation has been shown to prevent cGVHD (8),
suggesting a significant role for de novo thymic-derived T cells in
this pathology.
In this study, we aimed at further investigating the biology of
cGVHD and its effects on T cell homeostasis. Given the role that
T cell immunity plays in cGVHD, we prospectively evaluated T
cell reconstitution and thymic function in a homogenous patient
population undergoing allo-HSCT after a reduced intensity
conditioning (RIC) regimen containing ATG. We assessed the
kinetics of T cell reconstitution after allo-HSCT and performed
a comparative analysis of patients developing cGVHD vs. those
who did not.
MATERIALS AND METHODS
Patients and Sample Collection
We prospectively monitored 57 patients undergoing allo-HSCT
at Hospital de Santa Maria (Centro Hospitalar Universitário
Lisboa Norte) from unrelated donors after a RIC regimen
containing fludarabine 30 mg/m2/day for 5 days (D-8 to D-
4), melphalan 70 mg/m2/day for 2 days (D-3 and D-2), and
ATG (thymoglobulin) 4–6 mg/Kg (total dose) divided in 2–
3 days, according to HLA compatibility. GVHD prophylaxis
consisted of cyclosporine A (CsA) plus mycophenolate mofetil
(MMF) in all patients. CsA and MMF were initiated on D-1 with
CsA at 3 mg/kg/day intravenously (iv) twice daily and MMF
at 2 g/day (iv or per os). CsA blood levels were monitored to
target levels of 200 ng/mL. In the absence of GVHD, immune
prophylaxis was tapered and discontinued betweenmonths 6 and
9 post-transplant.
Our center has acquired a significant experience with the
administration of thymoglobulin in unrelated donor allo-HSCT
over the last decade and maintained the same protocol in the
present patient cohort.
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Seventeen patients were excluded due to early disease relapse
or death from either infection or aGVHD in the first 9 months
post-transplant. Chronic GVHD diagnosis and staging were
performed according to the 2014 NIH criteria (19). Patient and
donor characteristics are shown in Table 1. Peripheral blood was
collected on months 1, 2, 3, 6, 9, 12, 18, and 24 after HSCT, and
from five healthy controls (HC). Up to 2 weeks of variance in
sample collection was allowed for patient sample collection.
Written informed consent was obtained before sample
collection in accordance with the Declaration of Helsinki. This
study obtained approval from the Ethics Committee of Lisbon
Academic Medical Center (ref. 459/13).
Flow Cytometry
Flow cytometry analysis was performed on fresh whole blood,
at pre-determined fixed time-points as indicated above, using
the Human Regulatory T Cell Whole Blood Staining Kit
(eBioscience), according to the manufacturer’s instructions and
immediately acquired on a LSR Fortessa (BD Biosciences).
The following monoclonal antibodies were used: Bcl-2
(Bcl-2/100) and CD31 (WM-59) FITC; Ki-67 (20Raj1) and
CD95 (DX2) PE; CD3 (OKT3) PerCPCY5.5, CD45RA (HI100)
and CD25 (M-A251) PE-CY7; CD4 (RPAT4) APC; CD127
(eBioRDR5) and CD62L (DREG-56) APCeFlour780 and FoxP3
(PCH101) e450 (all from eBioscience, except for CD25 PE-
CY7, Becton Dickinson). Daily flow cytometer quality control
monitoring was performed using Cytometry Setup and Tracking
Beads (Becton Dickinson). Eight peak calibration Rainbow Beads
(Becton Dickinson) were used to ensure stable fluorescence
measurements throughout the study. Data was analyzed without
prior knowledge of cGVHD status, using FlowJo9 R©. For
quantification of Ki-67, Bcl-2, and CD95 within T cell subsets
a cutoff of 50 events was used as a valid data point for
statistical analysis. Five healthy control samples were stained in
the same conditions.
CD4 and CD8T Cell Receptor (TCR)
Repertoire Analysis
TCR Diversity was evaluated with a TCRβgene (TRB)
complementarity-determining region 3 (CDR3) spectratyping
assay, performed on patient samples from either early (month
3) or late (month 9 or 12) time-points post-HSCT, as previously
described (20). Cryopreserved PBMC from a separate set of 8
healthy controls, 10 patients with, and 10 without cGVHD were
thawed, stained for CD3, CD4 and CD8, and FACSorted (BD
FACSAria III) into CD4 and CD8T cells. Total RNA isolated
from each cell fraction (AllPrep, Qiagen) was used for first-strand
cDNA synthesis primed with an equivolume mixture of random
hexamers and oligo (dT) (Invitrogen Superscript III). TCRβ
transcripts were amplified with TRBV family specific primers
and a common TRCB reverse primer (21, 22). A run-off reaction
with a second TRCB FAM-labeled primer was used to extend
these products. Each fluorescent TRBV-TRBC fragment was
separated using capillary electrophoresis-based DNA automated
sequencer. Data were analyzed with GeneMapper (Thermo
Fischer Scientific) for size, peak count, and fluorescent intensity
determination. Profiles of transcript TRB repertoires were
TABLE 1 | Patient/donor characteristics.
cGVHD No cGVHD
Patients 18 22
Gender 6 F; 12M 12F; 10 M











CMV Positive 14 18
DONORS
Gender 11 F; 7M 9F; 13 M
Age 35 (21–49) 32 (20–57)
Female Donor to Male Patient 6 4
CMV Pos 12 15
HLA MATCHING
10/10 8 9
9/10 9 (3A, 1B, 4C, 1DQB1) 12 (8A, 1B, 2C,
1DQB1)













Day of cGVHD Onset 230 (149–455) –
Follow Up (days) 682 (286–1,051) 483 (90–840)
classified based on peak count, distribution shape and relative
fluorescence intensity (RFI) of each peak (% RFI = 100 × clonal
peak area/total peak area) (23).
Signal-Joint TCR Excision Circle (sjTREC)
Quantification in CD4 and CD8T Cells
sjTREC sequences were analyzed with a multiplex qPCR assay
(24) in CD4 and CD8T cells using the same samples purified
for the diversity studies. sjTREC sequence copy numbers were
extrapolated from standard curves obtained by 10-fold serial
dilutions of a triple-insert plasmid containing sjTREC and TRAC
fragments in a 1:1:1 ratio (kind gift from L. Imberti, Spedali
Civili of Brescia, Italy). Detected sjTREC copies were genome
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normalized with the mean quantity of T cell receptor α-chain
sequences. Results were expressed as sjTREC copies per 106 CD4
or CD8T lymphocytes.
Statistical Analysis
The patients’ clinical data shown in Table 1 was compared
using Fisher’s exact test and the Mann–Whitney test when
comparing continuous data. Data obtained for patients with and
without cGVHD were compared at each time-point using the
Mann-Whitney test on GraphPad Prism R©. To analyze slopes
of reconstitution early (up to 6 months) and late (from 6
months onwards) post-HSCT, we used linear mixed effects
(LME) models over those two periods. In this approach, the data
of all patients over time is analyzed together, with patient as the
random effect, while time and cGVHD (yes/no) are covariates.
In each case, we tested also for an interaction term of cGVHD
with time (i.e., different slopes of reconstitution). Previous
aGVHD, gender, and source of graft were further included
as covariates. In all cases, statistical significance was assessed
at α = 0.05.
RESULTS
Patient Characteristics
All patients underwent allo-HSCT from an unrelated donor
and received the same conditioning and GVHD prophylaxis
regimens, as described in the methods section. Patient and
donor characteristics are summarized in Table 1. The most
frequent underlying disease within patients included in the
analysis was AML (42.5%) and 60% of transplants used
PBSC as the source of graft. After a 24-month follow-
up post-HSCT, 18 patients developed cGVHD while 22 did
not (No cGVHD). Median cGVHD onset day was 230.
Patients without cGVHD had a shorter follow-up compared
to cGVHD patients. Seventeen out of 18 cGVHD patients
had previously developed aGVHD, in contrast to 9 out of
22 in the No cGVHD group. No significant differences were
identified when comparing the patient characteristics between
groups (Table 1), with the exception of the higher incidence of
aGVHD in patients with cGVHD (p = 0.0006). Five healthy
controls (HC), with a median age of 43 (range 36–45), were
also studied.
Distinct Treg, Tcon, and CD8
Reconstitution Patterns After HSCT
Treg numbers were low in both patient groups up to month
6 after HSCT (Figure 1A). From months 9 to 18, Treg were
decreased in cGVHD vs. No cGVHD patients. Analysis of
ex vivo proliferation using intracellular Ki-67 staining revealed
significantly decreased proliferation from months 3 to 18 in
patients developing cGVHD as compared to No cGVHD,
suggesting that reduced Treg numbers in cGVHD may be partly
due to reduced homeostatic proliferation (Figure 1B).
Lower Treg numbers in cGVHD were not associated with
increased susceptibility to apoptosis as assessed by Bcl-2 and
CD95 expression levels, as these proteins were expressed at
similar levels in both patient groups (Figures 1C,D). These data
suggest that apoptosis mediated by these pathways did not play a
major role in the low Treg numbers observed in cGVHD.
We further quantified conventional CD4T (Tcon; Foxp3−
CD4) and CD8T cell numbers and found no major differences
between patients with and without cGVHD (Figure 1A). We did
observe significant reductions in Tcon and CD8 proliferation, as
assessed by Ki-67 staining, in cGVHD compared to No cGVHD
(Figure 1B). On the other hand, no clear trend for altered Bcl-2
or CD95 expression in cGVHD was observed (Figures 1C,D).
Impaired Naive and SCM Treg
Reconstitution in cGVHD
Quantification of Naive/memory Treg subsets was performed
by flow cytometry as described in the methods using CD45RA,
CD62L, and CD95 surface markers. We identified Central
Memory (CM) cells as CD45RA− CD62L+, Effector Memory
(EM) as CD45RA− CD62L− and CD45RA-expressing Terminal
effectors (EMRA) as CD45RA+ CD62L−. We further used
CD95 to distinguish Naive, CD45RA+ CD62L+CD95−, from the
Stem Cell Memory (SCM) subset, CD45RA+ CD62L+CD95+,
as previously described (25) (detailed gating strategy illustrated
in Supplementary Figure 1A). The percentages of each subset
within Treg from patients with and without cGVHD is
summarized in Figure 2A. A detailed visualization of the overall
data showing percentage and absolute counts for each subset
in all time-points for both patient groups and healthy controls,
as well as the corresponding significances, is displayed in
Supplementary Figure 1B.
The most prevalent subset within Treg was CM, followed
by EM, naïve, and SCM, while EMRA were an extremely
rare subset (Figure 2A). We observed decreased Naive Treg
percentages and absolute counts in cGVHD as compared to
No cGVHD throughout the follow-up (Figures 2A,C). The only
exception was at Month 1 when Naive Treg frequency and
absolute counts were increased in cGVHD vs. No cGVHD
patients (Figures 2A,C). Despite this, Naive Treg remained low
in patients developing cGVHD while they increased in the
absence of cGVHD. This trend, reflecting an inability of Naive
Treg to recover in patients developing cGVHD, was confirmed
in a LME analysis of the first 6 months post-HSCT. This
analysis showed significantly different slopes estimated for the
recovery of Naive percentages, whereby Naive Treg percentages
only increased in the absence of cGVHD (Figure 2B). From
month 9 onwards, Naive Treg percentages and counts were lower
in patients developing cGVHD as compared to patients that
remained free from cGVHD (Figures 2A,C).
Similar to Naive Treg, the recovery of the SCM Treg subset
was impaired in patients developing cGVHD. This was the case
for percentages and for absolute counts, which were significantly
reduced in cGVHD from month 9 to 18 (Figures 2A,D). The
relative proportion of the remaining memory subsets was largely
unaltered by cGVHD (Figure 2A). CM and EM Treg absolute
counts were either similar or reduced in cGVHD, whereas
EMRA Treg were similar or increased, but no sustained statistical
significances were noted (refer to Supplementary Figures 1B,C
for details).
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FIGURE 1 | Treg, Tcon and CD8 Homeostasis following HSCT. Patients were divided into No cGVHD (gray lines and open circles) and cGVHD (black lines and
squares). Healthy controls (HC) are also shown (gray diamonds and dotted gray lines). (A) Absolute counts per microliter for Treg (CD3+ CD4+ CD25bright Foxp3+
CD127low), Tcon (CD3+ CD4+ Foxp3−), and CD8 (CD3+ CD4−) T cells. (B) Frequency of Ki-67+ cells within CD3+ CD4+ Foxp3+ Treg, Tcon, and CD8T cells.
Median fluorescence intensity (MFI) for Bcl-2 (C) and CD95 (D) within CD3+CD4+ Foxp3+ Treg, Tcon and CD8T cells. Symbols represent median values and
whiskers represent interquartile range (IQR). Asterisks denote statistically significant differences between patient groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01).
In summary, cGVHD was associated with impaired
Treg recovery, particularly of the Naive and SCM Treg
subsets, and lower Treg proliferation as compared to the No
cGVHD group.
Impaired Naive and SCM Tcon
Reconstitution in cGVHD
Chronic GVHD was associated with a marked impairment in
Naive Tcon recovery as compared to patients who did not develop
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FIGURE 2 | Treg subset reconstitution in cGVHD. Treg were identified as CD4+ Foxp3+ within a CD3+ lymphocyte gate. Naive and memory subsets were identified
as shown in Supplementary Figure 1. (A) The median percentage for each subset within Treg is shown for patients with and without cGVHD, as well as for HC.
(B) Naive Treg percentages in the first 6 months after HSCT in patients with cGVHD (black line) and No cGVHD (dotted gray line), illustrating the results of the LME
analysis for this subset. Absolute counts of Naive (C) and SCM (D) Treg in patients without cGVHD (gray lines and open circles), with cGVHD (black lines and squares)
and HC (gray diamonds and dotted gray lines). Symbols represent median values and whiskers represent IQR. Asterisks denote statistically significant differences
between patient groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01).
cGVHD. This became apparent from month 9 onwards in terms
of both frequency and absolute counts (Figures 3A,C). Although
differences between patient groups only reached significance after
month 9, the LME analysis revealed that the percentage of Naive
Tcon up to month 6 was better represented by a model with
significantly different slopes for cGVHD and No cGVHD (p
= 0.008) (Figure 3B). Hence, during the first 6 months after
HSCT, Naive Tcon percentages increased in patients who did
not subsequently develop cGVHD, while they remained stable
in patients who develop cGVHD. This translated, at later time-
points, into significant differences in Naive Tcon frequencies
and numbers between patient groups from months 12 to 24
(Figures 3A,C; Supplementary Figures 1B,C). Impaired Naive
Tcon recovery in cGVHDwas mimicked by decreased SCM Tcon
levels, reaching significance at month 18 for SCM Tcon counts
(Figures 3A,D).
CM and EMwere the most abundant Tcon subsets post-HSCT
and were largely similar between patient groups, while EMRA
showed a non-significant tendency to be increased in cGVHD
(Figure 3A). Percentages and absolute counts for all Tcon subsets
are detailed in Supplementary Figures 1B,C.
In summary, we did not observe significant disparities in
whole Tcon recovery between patients developing cGVHD and
those who did not. However, the composition of the Tcon pool
after HSCT reveals an impairment in Naive and SCM subsets
in patients who develop cGVHD, similar to what was observed
in Treg.
Increased CD8 Naive, SCM, and EMRA in
cGVHD
The reconstitution of Naive and memory subsets within
the CD8T cell pool differed greatly between patient groups
(Figure 4) and had a strikingly different pattern to that observed
in Tcon and Treg. This was particularly prominent not only for
the least abundant Naive and SCM CD8 subsets, but also for the
more abundant, terminally differentiated EMRA subset.
Interestingly, we observed significantly increased Naive CD8
percentages and counts in cGVHD vs. No cGVHD during
the initial post-transplant period (Figures 4A,C). This statistical
significance disappeared from month 12 onwards, as Naive
CD8 increased in patients who did not develop cGVHD. Such
accelerated Naive CD8T cell recovery in the absence of cGVHD
at later time-points was also revealed by the LME analysis of
months 9 to 24 post-HSCT. This analysis showed a significant
difference in the slopes for Naive CD8 percentages between the
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FIGURE 3 | Naive and memory Tcon reconstitution in cGVHD. Tcon were identified as CD4+ Foxp3− within a CD3+ lymphocyte gate. Naive and memory subsets
were identified as shown in Supplementary Figure 1. (A) The percentage of each subset within Tcon cells is shown for patients with and without cGVHD, as well as
HC. (B) Percentage of Naive within Tcon in the first 6 months after HSCT in patients with cGVHD (black line) and No cGVHD (dotted gray line), illustrating the results of
the LME analysis for this subset. Naive (C) and SCM (D) Tcon absolute counts in patients without cGVHD (gray line and circles), patients with cGVHD (black line and
squares) and HC (gray diamonds and dotted gray lines). Median values and IQR are shown. Asterisks denote statistically significant differences between patient
groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01; ***p = 0.0001 to 0.001).
two patient groups (Figure 4B). While in patients with cGVHD
the percentage of Naive CD8 stabilized, in the absence of cGVHD
the frequency of these cells increased over time.
Interestingly, the SCM CD8 subset was also increased in
patients developing cGVHD vs. No cGVHD, starting from the
early time points of the follow-up period, both in percentages and
absolute counts (Figures 4A,D).
Despite such prominent differences in Naive and SCM
subsets, these were always the least abundant populations.Within
the most frequent populations the EMRA showed the most
striking differences between patient groups. Hence, terminally
differentiated EMRA CD8 cells were increased in percentage
and counts from the very early post-transplant period in
patients developing cGVHD (Figures 4A,E), while the remaining
memory subsets, CM and EM, showed an opposite pattern
to that observed in Naive, SCM and EMRA, with significant
reductions in percentages being noted in patients developing
cGVHD (Figure 4A; Supplementary Figures 1B,C).
In summary, CD8T cell reconstitution in cGVHD was
associated with persistently increased Naive, SCM and EMRA
subsets. This became apparent very early after HSCT, suggesting
a possible involvement of these subsets in disease development.
The Effects of Acute GVHD on SCM Tcon
and CD8
In our patient cohort, all but one of the patients developing
cGVHD had a history of previous aGVHD, while within
the group of 22 patients who did not develop cGVHD, 9
had developed acute GVHD (aGVHD). In order to clarify
the contribution of aGVHD and the associated therapies to
differences in T cell reconstitution between patient groups,
we tested the effect of adding aGVHD as a covariate in
the LME analysis. This analysis showed that during the
first 6 months after HSCT, SCM Tcon and CD8 percentages
and counts were significantly affected by aGVHD (p <
0.01). No impact of aGVHD was observed from month
6 onwards.
To complement this analysis, we stratified the No cGVHD
group into acute only (Ac GVHD, n = 13) and no GVHD at
all (No GVHD, n = 9). The only patient in our cohort who
did not have aGVHD prior to cGVHD was excluded from this
analysis. Hence, the chronic GVHD group consisted of patients
with acute and chronic GVHD (Ac & Ch GVHD, n= 17). Month
24 was excluded from this analysis due to insufficient number of
data points.
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FIGURE 4 | Naive and memory CD8 reconstitution in cGVHD. CD8T cells were identified as CD3+ CD4− lymphocytes. Naive and memory subsets were identified as
shown in Supplementary Figure 1. (A) Percentage of each subset within CD8 cells for patients with and without cGVHD, as well as HC. (B) Naive CD8 percentages
from month 9 to 24 after HSCT in patients with cGVHD (black line) and no cGVHD (dotted gray line), illustrating the results of the LME analysis for this subset.
Absolute counts of Naive (C), SCM (D), and EMRA (E) CD8 cells in patients without cGVHD (gray circles and dotted lines), patients with cGVHD (black squares and
lines) and HC (gray diamonds and dotted gray lines). Symbols represent median values and whiskers represent IQR. Asterisks denote statistically significant
differences between patient groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01; ***p = 0.0001 to 0.001).
Stem Cell Memory (SCM) Tcon numbers were significantly
increased during the first 3 months in GVHD vs. No GVHD
patients (Figure 5A). At later time-points, this pattern was
reversed and while SCM Tcon reconstituted in the No GVHD
and Ac GVHD groups, they became significantly reduced in the
Ac & Ch GVHD patient group. A similar pattern was observed
when analyzing SCM percentages within Tcon (data not shown).
Overall, these data suggest that GVHD development is associated
to early increases in SCM Tcon.
For CD8T cells, initial time-points showed a similar
reconstitution pattern to Tcon, whereby patients with GVHD
showed significantly increased SCM as compared to No GVHD
(Figure 5B). Interestingly, from month 6 onwards patients with
aGVHD showed similar SCM CD8 counts as patients who did
not develop any form of GVHD. On the other hand, patients
who subsequently develop cGVHD appear to sustain a significant
increase in this population throughout the follow-up period
when compared to the other two groups of patients. A similar
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FIGURE 5 | The effect of acute GVHD on SCM Tcon and CD8 reconstitution.
SCM absolute counts for Tcon (A) and CD8 (B) in patients without any form of
GVHD (No GVHD, white bars), patients with acute GVHD only (Ac GVHD, gray
bars), patients with acute and chronic GVHD (Ac & Ch GVHD, black bars) and
healthy controls (HC, gray diamonds). Bar graphs shows median values and
IQR. Asterisks denote statistically significant differences between patient
groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01).
pattern was observed when analyzing SCM percentages within
CD8 (data not shown).
These data suggest that GVHD development is associated to
early increase in the SCM subset after transplant. Furthermore,
we observed a sustained increase in this CD8 subset in patients
who subsequently develop cGVHD, further pointing to a possible
role for these cells in disease development.
Chronic GVHD Is Associated With Reduced
CD4 TCR Vβ Diversity
TCR repertoire diversity was analyzed in purified CD4
and CD8T cells from patients at early (month 3) and
late time-points (months 9 or 12) post-HSCT by TCRVB
spectratyping (Figure 6).
Early post-HSCT, we observed no significant differences in
TCR diversity between patient groups in either CD4 or CD8
cells (Figures 6B,D). There were few VB families displaying
polyclonal distributions, while those with skewed, oligoclonal,
and monoclonal distributions prevailed (Figures 6A,C). When
early and late time-points were compared within each patient
group, significant increases in TCR diversity were observed,
suggesting de novo CD4 and CD8T cell production during
patient follow-up.
However, when patients developing cGVHD were compared
to No cGVHD, a significant reduction in CD4 TCR diversity in
cGVHD was observed at later time-points (Figure 6B). This was
reflected in decreased prevalence of polyclonal Gaussian profiles
and the appearance of numerous skewed profiles (Figure 6A),
translating into decreased TCRVB peaks within CD4T cells in
cGVHD (Figure 6B).
Similarly to CD4, we observed an increase in TCR diversity
from early to late time-points in CD8. However, the median
number of CDR3 peak count within the VB families did not
show statistically significant differences between patient groups
(Figure 6D). This was likely the result of the observed high
prevalence of skewed distributions in CD8T cells from both
patient groups (Figure 6C).
Chronic GVHD Negatively Impacts Thymic
Function
We next analyzed sjTREC content as an estimate of thymic
activity in purified CD4 and CD8T cells at early (month 3) and
late (months 9 or 12) time-points post-HSCT. Unfortunately,
insufficient cell numbers precluded the analysis at month 3.
sjTRECs were significantly reduced in CD4 (Figure 7A) and
CD8 (Figure 7C) T cells in cGVHD vs. No cGVHD patients at
late time-points.
Importantly, sjTREC content and Naive counts from all
patients were positively correlated in CD4 (Figure 7B) but not
in CD8T cells (Figure 7D). Furthermore, Naive CD4 counts
were positively correlated with sjTRECs in No cGVHD, but not
in cGVHD (data not shown). In CD8T cells, no significant
correlation was observed between sjTREC content and Naive
CD8 counts in either patient group (data not shown).
The presence of a significant correlation between CD4 TREC
numbers and Naive CD4 counts at month 9 suggests that the
Naive CD4T cell reconstitution observed in patients who do
not develop cGVHD is likely the result of de novo thymic
production. On the other hand, the increase in Naive CD8T cells
observed in patients with cGVHD may depend more on T cell
peripheral expansion.
Recent Thymic Emigrant (RTE) Tcon and
Treg in GVHD
The expression of CD31 within Naive CD4T cells has been
reported to contain a population enriched in RTE (26). We
therefore quantified this population in our patient cohort
as an additional measure of thymic function. We found
that patients developing cGVHD had significantly reduced
RTE Treg (Figure 7E) and Tcon (Figure 7F) from month 9
onwards. Furthermore, LME analysis of the first 6 months
revealed significantly different slopes for RTE Tcon absolute
counts (Figure 7H) and percentages (p = 0.0032) (data
not shown), whereby RTE Tcon increase in the absence of
cGVHD with negligible recovery of this population in patients
developing cGVHD.
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FIGURE 6 | TCR repertoire analysis in HSCT patients and controls. TCRVB diversity analysis was performed on purified CD4 and CD8T cells from healthy controls
(HC) and patients with (cGVHD) and without cGVHD (No cGVHD). Data shown represent values obtained from patient samples early (month 3) and late (months 9 or
12) after HSCT. Clonality analysis of TRB locus transcripts is displayed as profile frequencies of CDR3 spectratypes for TRVB1 to TRVB24 gene families. Profiles were
classified on the basis of peak number, distribution shape and relative fluorescence intensity (RFI) as: polyclonal Gaussian (PG, ≥8 peaks with a Gaussian distribution),
polyclonal non-Gaussian (PNG, ≥8 peaks with an uneven distribution), polyclonal skewed (PS, 6 peaks or 1 peak with RFI>40%), polyclonal severely skewed (PSS, 1
or 2 peaks with RFI>70%), oligoclonal (O, 2 to 3 peaks), monoclonal (M, 1 peak or a peak with RFI>90%), and not detected (ND). Color stacked columns represent
the mean frequency for each of the clonality profiles in CD4 (A) and CD8 (C) in HC, as well as in patients with and without cGVHD early and late after HSCT.
TRVB1-24 CDR3 median peak count in CD4 (B) and CD8 (D) T cells for HC and patient groups. Asterisks denote statistically significant differences between patient
groups (**p = 0.001 to 0.01; ***p = 0.0001 to 0.001;****p < 0.0001).
The addition of aGVHD as a variable to the LME analysis of
RTE Treg and Tcon showed that aGVHD was associated with
increased RTE Tcon counts and percentages during the first 6
months post-HSCT (p < 0.01). No effect was observed at later
time-points. Accordingly, when the No cGVHD patient group
was split into No GVHD and aGVHD only as described earlier,
RTE Tcon were significantly decreased in No GVHD vs. both
GVHD patient groups at months 1, 2, and 3 (Figure 7G). After
month 6, RTE Tcon counts increased in No GVHD and Ac
GVHD, while Ac & Ch GVHD patients showed significantly
reduced RTE Tcon numbers, suggesting that cGVHDmay impact
on RTE Tcon reconstitution.
DISCUSSION
Chronic GVHD remains a major hurdle in allo-HSCT.
The significant role played by T lymphocytes in cGVHD
pathophysiology has been highlighted in studies that identify
graft T cells as major mediators in GVHD development, with
Naive T cells playing a central role (27). This has led to
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FIGURE 7 | sjTREC content and RTE analysis post-HSCT. sjTRECs were quantified in purified CD4 (A) and CD8 (C) T cells at months 9 and 12 post-HSCT. Median
and IQR values for sjTREC content are shown per 106 CD8 or CD4T cells in healthy controls (HC, gray diamonds), patients without cGVHD (No cGVHD, white
(Continued)
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FIGURE 7 | circles), and patients with (cGVHD, dark gray squares). Linear regression analysis between Naive CD4 (B) or CD8 (D) absolute counts and sjTREC
content where black squares represent cGVHD and while circles No cGVHD patients. Absolute counts of RTE Treg (E) and RTE Tcon (F) in patients with (black lines
and squares) and without (gray lines and circles) cGVHD, as well as in HC (gray diamonds and gray dotted lines). (G) RTE Tcon counts in patients without GVHD (No
GVHD, white bars), with acute GVHD only (Ac GVHD, gray bars), with acute and chronic GVHD (Ac & Ch GVHD, black bars), and in HC (gray diamond). (H) RTE Tcon
counts on the first 6 months after HSCT in patients with (cGVHD, black line) and without (No cGVHD, dotted gray line) cGVHD, illustrating the results of the LME for
these subsets. Median and IQR values are shown. Asterisks denote statistically significant differences between patient groups (*p = 0.01 to 0.05; **p = 0.001 to 0.01;
***p = 0.0001 to 0.001).
the development of T cell depletion strategies that, despite
reducing GVHD incidence, are associated with delayed immune
reconstitution and increased relapse (28). In order to further
study the role played by naive and memory T cell subsets in
cGVHD in a setting of partial in vivo T cell depletion, we
studied a homogenous cohort of patients undergoing unrelated
donor allo-HSCT up to 24 months after transplant. This patient
cohort was transplanted at a single institution, received the same
ATG-containing RIC and GVHD prophylaxis regimens. Hence,
despite the negative effects of some immunosuppressive drugs
such as CsA, which negatively impacts on Treg function (29),
all patients were under the same regimen during the initial
post-transplantation period. After 6–9 Months post-HSCT, CsA
was discontinued in patients who did not present cGVHD and
therefore findings at these later time points may relate to both
cGVHD development and/or the immunosuppressive regimen.
In this setting, we observed 45% cGVHD incidence (27.5%
moderate and severe), likely associated to the fact that 13 out of
the 18 patients received PBSC as the graft source and that the
majority of these patients had some degree of HLA mismatch
with their donors.
While most reports focus on the effects of ATG on cGVHD
incidence and immune reconstitution, we investigated the
association between naive and memory T cell homeostasis and
cGVHD after an ATG-containing conditioning regimen, which
is understudied. All our patients received thymoglobulin in the
conditioning regimen, which is one of the available rabbit ATGs.
Since all of these lymphocyte depleting products are different, it is
possible that immune reconstitution in patients receiving another
ATG could be somewhat different.
We performed a phenotypic study of T cell reconstitution
evaluating Naive, CM, EM, and EMRA reconstitution at fixed
time-points after HSCT. We further extend previous studies
looking at T cell subsets in cGVHD by investigating the
reconstitution of a recently described T cell subset with unique
characteristics. SCM have been described as a subset of memory
T cells with a Naive-like phenotype, that includes CD45RA,
CD62L, and CCR7, that can be distinguished from Naive T
cells by the expression of CD95 (30). SCM T cells originate
from in vivo priming of Naive T cells and possess stem-cell-like
properties, being able to generate other memory subsets (25, 30,
31), and are therefore thought to play a role in the maintenance
of long term memory. In addition, increased SCM have been
associated to autoimmune conditions (32, 33). In order to study
the mechanisms involved in T cell reconstitution, we further
evaluated proliferation through Ki-67 expression, susceptibility
to apoptosis through Bcl-2 and CD95 levels, and evaluated
thymic production of CD4T cells through the identification of
CD31-expressing RTE. At selected time-points, we performed
TCR diversity and TREC content analysis. Despite the inherent
variability of studies performed in human subjects with a distinct
genetic makeup, we report interesting observations that shed
some light into the biology of cGVHD in humans.
We observed altered Treg homeostasis in patients developing
cGVHD. This is consistent with previous reports from our group
and others, in the setting of multiple conditioning and GVHD
prophylaxis regimens, showing impaired Treg reconstitution in
cGVHD (34–37). Reduced Treg in cGVHD was not associated
with altered expression of the apoptosis-related proteins Bcl-2
and CD95, but correlated with decreased proliferation, possibly
associated with immunosuppressive therapies. Importantly, we
demonstrate a clear association between cGVHD development
and severely impaired Naive and SCM Treg reconstitution
in this setting. Decreased Naive Treg may result from
reduced thymic output following GVHD-induced thymic
damage. Indeed, we found significantly decreased levels of the
RTE-enriched CD45RA+CD62L+CD31+ subset, a population
that has been used as an indicator of thymic production,
within Treg in cGVHD (26, 38). Decreased SCM Treg may
result from decreased Naive Treg and/or differentiation into
memory phenotypes.
Overall, our data on Treg subset reconstitution support the
hypothesis that imbalances in T cell tolerance play an important
role in the biology of cGVHD and reinforces the potential
benefits of Treg-restoring therapies, particularly of Naive Treg as
this subset is particularly depleted in cGVHD.
In line with the previously reported negative impact of
ATG on CD4T cell reconstitution (39–41), Tcon recovery was
impaired in both patient groups. However, we did not find
significant differences in total Tcon numbers when comparing
patients with and without cGVHD. Nevertheless, we report
significantly distinct Tcon subset composition when comparing
both patient groups. Notably, Naive and SCMTcon recovery were
impaired in patients developing cGVHD. This was accompanied
by a tendency for increased levels of the more differentiated
subsets EM and EMRA in patients with cGVHD
T cell reconstitution is thought to occur through peripheral
expansion and de novo thymic production (42, 43). In order
to investigate the pathways leading to impaired Naive Tcon
reconstitution, we measured ex vivo proliferation throughout the
follow-up, using Ki-67 as a proliferation marker. We observed
a tendency for reduced Ki-67 expression within total Tcon,
as well as in Tcon subsets (data not shown), in patients
developing cGVHD. Susceptibility to apoptosis, as assessed
by the quantification of Bcl-2 and CD95 expression levels,
was similar between patient groups, pointing to decreased
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homeostatic proliferation as a contributing factor to impaired
Naive Tcon reconstitution.
In order to have a measure for de novo thymic production,
we quantified sjTREC in total CD4T cells. TRECs are episomal
DNA sequences formed during thymic T-cell development by
TCR V-J gene rearrangements that correlate with thymopoiesis,
particularly in the absence of extensive proliferation (44).
sjTRECs were significantly reduced in CD4T cells from
cGVHD versus No cGVHD patients. Interestingly, CD4 sjTREC
correlated with Naive CD4 numbers, suggesting that, in the
absence of cGVHD, the Naive Treg and Tcon recovery is likely
to result from de novo thymic production occurring after HSCT
(45). In order to further detail the contribution of thymic output
to CD4T cell recovery post-transplant, we quantified RTE Tcon.
We show that frommonth 9 onwards, RTE Tcon increased in the
absence of cGVHD while patients who develop cGVHD show a
severely impaired RTE reconstitution. It is therefore likely that
a combination of decreased proliferation and impaired thymic
output leads to impaired Naive Tcon and Treg reconstitution
in cGVHD. In addition, CD4 TCRVB diversity was significantly
reduced in patients, more so in cGVHD, further pointing to
impaired thymic production in patients developing cGVHD.
When accessing the role played by acute GVHD in RTE Tcon
recovery after HSCT, we found increased RTE Tcon at months
1–3, both in Acute GVHD and in Acute and Chronic GVHD
patients, as compared to No GVHD. This suggests a potential
deleterious role of RTE Tcon early after HSCT. It is unclear if
these cells are of thymic origin or result from cytokine-driven
proliferation of infused RTE (46). We speculate that RTE Tcon
detected early after HSCT may contain self-reactive clones, while
RTE Tcon present at later time-points in No cGVHD result from
adequate thymic selection processes.
Overall, we observed impaired Naive and SCM Tcon
reconstitution in cGVHD, associated with reduced peripheral
expansion. In addition, decreased TREC content and RTE Tcon
recovery further suggest that cGVHD results from alterations in
de novo thymic production. Intriguingly, we found that cGVHD
development was associated to increased RTE Tcon early after
HSCT through yet undescribed mechanisms.
It is noteworthy that we report a distinct picture emerging for
CD8T cells. EM, EMRA and CM were the most abundant CD8
subsets in the post-transplantation period. Interestingly, cGVHD
associated with increased Naive, SCM and EMRA as compared to
patients who did not develop cGVHD.
Stem Cell Memory (SCM) have been reported to differentiate
from Naive, to be increased in autoimmune disease (32, 33)
and to induce lethal GVHD in mouse studies (47). Our findings
of increased Naive and SCM CD8 in cGVHD vs. No cGVHD
raise the possibility that Naive CD8T cells may differentiate into
SCM and be involved in GVHD development by yet undescribed
mechanisms. Interestingly, when the effects of previous aGVHD
were taken into consideration in our statistical analysis, we
observed that during the first 6 months after transplant SCM
Tcon and CD8 were significantly affected by aGVHD. The
stratification of patient groups into No GVHD, Acute GVHD
only and Acute & Chronic GVHD confirmed that during these
initial stages after HCST patients developing GVHD show
increased numbers of these cells. A sustained increase in this
population in patients developing cGVHDwas observed for CD8
but not Tcon, further suggesting a potential role for CD8 SCM is
cGVHD development.
Other studies have shown that the thymus is a direct target
of GVHD (7) resulting on the emergence of self-reactive clones
and the autoimmunity associated to cGVHD (48, 49). We
observed a high prevalence of skewed and oligoclonal TCR
repertoires in CD8 from both patient groups. Interestingly, the
significantly reduced CD8 sjTREC content in cGVHD vs. No
cGVHD patients suggests reduced thymic output and/or a high
level of homeostatic proliferation observed in these patients.
Our data raises the possibility that increased Naive and
SCM CD8 present from early time-points after transplant in
cGVHD patients, may originate from defective negative selection
mechanisms resulting from thymic tissue damage, leading
to the output of self-reactive CD8 clones that may further
differentiate and mediate disease. Given the increased levels of
homeostatic T cell proliferation in the post-transplantation
period, we cannot exclude the possible contribution of
cell proliferation to the observed increase in Naive and
SCM CD8.
We therefore extend on the observations by Alho et al.
(34) that reported increased Naive T cell subsets in patients
developing cGVHD, by comparing patients with and without
cGVHD at month 3 after HSCT (34). We now show that this
occurs not only within Naive CD8 but also in the SCM CD8T
cell subset, by detailing increases in these cell populations in
patients who develop cGVHD in a cohort of patients undergoing
unrelated HSCT after an ATG-containing conditioning regimen.
We further show that this occurs in CD8T cells in a sustained
manner from month 1 to 9 in both percentages and absolute
counts. In addition, by stratifying our patient cohort with regards
to previous history of acute GVHD, we observed that increased
SCM in Tcon and CD8 occurs early after HSCT in patients
developing aGVHD. Of note, we did not observe any statistically
significant impact of adding aGVHD as a co-variate within the
Treg subsets.
In summary, we show that after an ATG-containing RIC
regimen, cGVHD development after allo-HSCT is associated
with reduced Treg recovery, particularly of Naive and SCM
subsets. We speculate that this is likely due to reduced
thymic production within the CD4T cell compartment, where
significantly decreased TCRVB diversity is observed in patients
developing cGVHD. We also show that cGVHD development is
associated to increases in Naive, SCM and EMRA CD8T cells.
This becomes apparent early after HSCT and persists throughout
our 24-month follow-up, suggesting a potential involvement of
these cells in the development of cGVHD.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of the Ethics Committee of Lisbon
Academic Medical Center with written informed consent
from all subjects. All subject gave written informed consent in
Frontiers in Immunology | www.frontiersin.org 13 March 2019 | Volume 10 | Article 334
Soares et al. T Cell Reconstitution in cGVHD
accordance with the Declaration of Helsinki. The protocol was
approved by Ethics Committee of Lisbon Academic Medical
Center (ref. 459/13).
AUTHOR CONTRIBUTIONS
MS analyzed data and wrote the paper. RA designed experiments,
performed experiments, analyzed data, and wrote paper. IF, SB,
and AR performed experiments. AV performed cell sorting and
flow cytometry support. PP and NC collected clinical data. DL
performed the spectratyping and TREC analysis. RR performed
statistical data analysis. AA and AS analyzed data. CM, FL, and
RM recruited patients. JR and JL conceived and designed the
study. JL recruited patients, designed experiments, and wrote
the paper.
FUNDING
This project received funding from: Fundacão para
a Ciência e Tecnologia, Portugal under the Harvard
Medical School–Portugal Program project: Induction of
Immune Tolerance in Human Allogeneic Hematopoietic
Stem Cell Transplantation (HMSP-ICT/0001/2011)
(JFLacerda PI), and UID/BIM/50005/2019, project
funded by Fundação para a Ciência e a Tecnologia
(FCT)/ Ministério da Ciência, Tecnologia e Ensino
Superior (MCTES) through Fundos do Orçamento de
Estado.
ACKNOWLEDGMENTS
Isolation, cryopreservation, and storage of
mononuclear cells was performed at iMM
Lisboa Biobank.
SUPPLEMENTARY MATERIAL




1. Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, et al. Is
the use of unrelated donor transplantation leveling off in Europe? The 2016
European Society for Blood and Marrow Transplant activity survey report.
BoneMarrow Transplant. (2018) 53:1139–48. doi: 10.1038/s41409-018-0153-1
2. D’Souza A, Lee S, Zhu X, PasquiniM. Current use and trends in hematopoietic
cell transplantation in the United States. Biol BloodMarrow Transplant. (2017)
23:1417–21. doi: 10.1016/J.BBMT.2017.05.035
3. Riddell SR, Appelbaum FR. Graft-versus-host disease: a surge of
developments. PLoS Med. (2007) 4:e198. doi: 10.1371/journal.pmed.0040198
4. Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E.
Pathophysiology of GvHD and other HSCT-related major complications.
Front Immunol. (2017) 8:79 doi: 10.3389/fimmu.2017.00079
5. Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the
prevention and treatment of chronic GVHD. Blood. (2017) 129:22–30.
doi: 10.1182/blood-2016-08-686659
6. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood.
(2014) 124:374–84. doi: 10.1182/blood-2014-01-514752
7. Fukushi N, Arase H, Wang B, Ogasawara K, Gotohda T, Good RA, et al.
Thymus: a direct target tissue in graft-versus-host reaction after allogeneic
bone marrow transplantation that results in abrogation of induction of self-
tolerance. Proc Nati Acad Sci USA. (1990) 87:6301–5.
8. Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M, Tanimoto M.
Donor-derived thymic-dependent T cells cause chronic graft-versus-host
disease. Blood. (2016) 109:1756–65. doi: 10.1182/blood-2006-08-042853
9. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS,
Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in
human chronic graft-versus-host disease. Blood. (2009) 113:3865–74.
doi: 10.1182/blood-2008-09-177840
10. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-
host disease.Haematologica. (2008) 93:1702–11. doi: 10.3324/haematol.13311
11. Alexander KA, Flynn R, Lineburg KE, Kuns RD, Teal BE, Olver SD, et al. CSF-
1–dependant donor-derived macrophages mediate chronic graft-versus-host
disease. J Clin Invest. (2014) 124:4266–80. doi: 10.1172/JCI75935
12. Cohen JL, Boyer O. The role of CD4+ CD25hi regulatory T cells in the
physiopathogeny of graft-versus-host disease. Curr Opin Immunol. (2006)
18:580–5. doi: 10.1016/j.coi.2006.07.007
13. Matsuoka K -I, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y,
et al. Low-dose Interleukin-2 therapy restores regulatory T cell homeostasis
in patients with chronic graft-versus-host disease. Sci Transl Med. (2013)
5:43–54. doi: 10.1126/scitranslmed.3005265
14. Hirakawa M, Matos T, Liu H, Koreth J, Kim HT, Paul NE, et al. Low-dose IL-2
selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. (2016)
1:e89278. doi: 10.1172/jci.insight.89278
15. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion
and beyond. Leukemia. (2007) 21:1387–94. doi: 10.1038/sj.leu.2404683
16. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA,
et al. Protective conditioning for acute graft-versus-host disease.N Engl J Med.
(2005) 353:1321–31. doi: 10.1056/NEJMoa050642
17. Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Anti-
lymphocyte globulin for prevention of chronic graft-versus-host disease. N
Engl J Med. (2016) 374:43–53. doi: 10.1056/NEJMoa1506002
18. Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM,
et al. Prospective, randomized, double-blind, phase III clinical trial of
anti–T-lymphocyte globulin to assess impact on chronic graft-versus-
host disease–free survival in patients undergoing HLA-matched unrelated
myeloablative hematopoietic cell transplantation. J Clin Oncol. (2017)
35:4003–11. doi: 10.1200/JCO.2017.75.8177
19. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al.
National Institutes of Health Consensus Development Project on Criteria for
Clinical Trials in chronic graft-versus-host disease: I. The 2014 Diagnosis
and Staging Working Group Report. Biol Blood Marrow Transplant. (2015)
21:389–401. doi: 10.1016/j.bbmt.2014.12.001
20. Azevedo RI, Soares MV, Albuquerque AS, Tendeiro R, Soares RS, Martins M,
et al. Long-term immune reconstitution of naive and memory t cell pools after
haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant. (2013) 19:703–12. doi: 10.1016/j.bbmt.2013.01.017
21. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P.
Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J
Immunol. (1994) 153:2807–18.
22. Currier JR, Deulofreut H, Barron KS, Kehn PJ, Robinson MA.
Mitogens, superantigens, and nominal antigens elicit distinctive
patterns of TCRB CDR3 diversity. Hum Immunol. (1996) 48:39–51.
doi: 10.1016/0198-8859(96)00076-6
23. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM,
Keyvanafar K, et al. Preferential suppression of trisomy 8 compared
with normal hematopoietic cell growth by autologous lymphocytes in
patients with trisomy 8 myelodysplastic syndrome. Blood. (2005) 106:841–51.
doi: 10.1182/blood-2004-05-2017
Frontiers in Immunology | www.frontiersin.org 14 March 2019 | Volume 10 | Article 334
Soares et al. T Cell Reconstitution in cGVHD
24. Sottini A, Ghidini C, Zanotti C, Chiarini M, Caimi L, Lanfranchi A,
et al. Simultaneous quantification of recent thymic T-cell and bone
marrow B-cell emigrants in patients with primary immunodeficiency
undergone to stem cell transplantation. Clin Immunol. (2010) 136:217–27.
doi: 10.1016/j.clim.2010.04.005
25. Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B,
et al. Generation of human memory stem T cells after haploidentical T-
replete hematopoietic stem cell transplantation. Blood. (2015) 125:2865–75.
doi: 10.1182/blood-2014-11-608539
26. Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, Möwes B, Radbruch A,
et al. Two subsets of naive T helper cells with distinct T cell receptor excision
circle content in human adult peripheral blood. J ExpMed. (2002) 195:789–94.
doi: 10.1084/jem.20011756
27. Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al.
Outcomes of acute leukemia patients transplanted with naive T cell–depleted
stem cell grafts. J Clin Invest. (2015) 125:2677–89. doi: 10.1172/JCI81229
28. Saad A, Lamb LS. Ex vivo T-cell depletion in allogeneic hematopoietic stem
cell transplant: Past, present and future. Bone Marrow Transplant. (2017)
52:1241–8. doi: 10.1038/bmt.2017.22
29. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J,
et al. Inhibition of CD4+CD25+ regulatory T-cell function by
calcineurin-dependent interleukin-2 production. Blood. (2006) 108:390–9.
doi: 10.1182/blood-2006-01-0329
30. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human
memory T cell subset with stem cell-like properties.Nat Med. (2011) 17:1290–
7. doi: 10.1038/nm.2446
31. Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, et al. In
vivo tracking of T cells in humans unveils decade-long survival and activity of
genetically modified T memory stem cells. Sci Transl Med. (2015) 7:273ra13.
doi: 10.1126/scitranslmed.3010314
32. Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, et al.
Memory stem T cells in autoimmune disease: high frequency of circulating
CD8+ memory stem cells in acquired aplastic anemia. J Immunol. (2016)
196:1568–78. doi: 10.4049/jimmunol.1501739
33. Roederer M, Quaye L, Mangino M, Beddall MH, Mahnke Y, Chattopadhyay
P, et al. The genetic architecture of the human immune system: a bioresource
for autoimmunity and disease pathogenesis HHS public access. Cell. (2015)
161:387–403. doi: 10.1016/j.cell.2015.02.046
34. Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al.
Unbalanced recovery of regulatory and effector T cells after allogeneic stem
cell transplantation contributes to chronic GVHD. Blood. (2016) 127:646–57.
doi: 10.1182/blood-2015-10-672345
35. Li Q, Zhai Z, Xu X, Shen Y, Zhang A, Sun Z, et al. Decrease of CD4+CD25+
regulatory T cells and TGF-β at early immune reconstitution is associated
to the onset and severity of graft-versus-host disease following allogeneic
haematogenesis stem cell transplantation. Leuk Res. (2010) 34:1158–68.
doi: 10.1016/J.LEUKRES.2010.03.017
36. Kawano Y, Kim HT, Matsuoka K -I, Bascug G, McDonough S, Ho VT, et al.
Low telomerase activity in CD4+ regulatory T cells in patients with severe
chronic GVHD after hematopoietic stem cell transplantation. Blood. (2011)
118:5021–30. doi: 10.1182/blood-2011-06-362137
37. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al.
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia
following allogeneic hematopoietic stem cell transplantation. J Clin Invest.
(2010) 120:1479–93. doi: 10.1172/JCI41072
38. Kilpatrick RD, Rickabaugh T, Hultin LE, Hultin P, HausnerMA, Detels R, et al.
Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol.
(2008) 180:1499–507. doi: 10.4049/JIMMUNOL.180.3.1499
39. Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, et al. Immune
recovery after allogeneic hematopoietic stem cell transplantation followingflu-
TBI versus TLI-ATG conditioning. Clin Cancer Res. (2015) 21:3131–9.
doi: 10.1158/1078-0432.CCR-14-3374
40. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P,
et al. Immune reconstitution after antithymocyte globulin- conditioned
hematopoietic cell transplantation. Cytotherapy. (2013) 14:1258–75.
doi: 10.3109/14653249.2012.715243.
41. Servais S, Menten-Dedoyart C, Beguin Y, Seidel L, Gothot A, Daulne C, et al.
Impact of pre-transplant anti-T cell globulin (ATG) on immune recovery
after myeloablative allogeneic peripheral blood stem cell transplantation. PLoS
ONE. (2015) 10:e0130026. doi: 10.1371/journal.pone.0130026
42. Boyman O, Létourneau S, Krieg C, Sprent J. Homeostatic proliferation and
survival of naïve and memory T cells. Eur J Immunol. (2009) 39:2088–94.
doi: 10.1002/eji.200939444
43. Grossman Z, Min B, Meier-Schellersheim M, Paul WE. Concomitant
regulation of T-cell activation and homeostasis. Nat Rev Immunol. (2004)
4:387–95. doi: 10.1038/nri1355
44. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes
BF, et al. Changes in thymic function with age and during the
treatment of HIV infection. Nature. (1998) 396:690–5. doi: 10.1038/
25374
45. Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N,
Gothot A, et al. Evidence for neo-generation of T cells by the thymus
after non-myeloablative conditioning. Haematologica. (2008) 93:240–7.
doi: 10.3324/haematol.11708
46. Azevedo RI, Soares MVD, Barata JT, Tendeiro R, Serra-Caetano A, Victorino
RMM, et al. IL-7 sustains CD31 expression in human naive CD4+ T
cells and preferentially expands the CD31+ subset in a PI3K-dependent
manner. Blood. (2009) 113:2999–3007. doi: 10.1182/blood-2008-07-1
66223
47. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al.
IL-7 and IL-15 instruct the generation of human memory stem T cells from
naive precursors. Blood. (2013) 121:573–84. doi: 10.1182/blood-2012-05-4
31718
48. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity
in graft-versus-host disease. Blood. (2005) 105:4885–91.
doi: 10.1182/blood-2004-12-4980
49. van den Brink MR, Moore E, Ferrara JL, Burakoff SJ. Graft-versus-
host-disease-associated thymic damage results in the appearance of T
cell clones with anti-host reactivity. Transplantation. (2000) 69:446–9.
doi: 10.1097/00007890-200002150-00026
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Citation: Soares MV, Azevedo RI, Ferreira IA, Bucar S, Ribeiro AC, Vieira A,
Pereira PNG, Ribeiro RM, Ligeiro D, Alho AC, Soares AS, Camacho N, Martins C,
Lourenço F, Moreno R, Ritz J and Lacerda JF (2019) Naive and Stem Cell
Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4
and CD8T Cells in Chronic Graft vs. Host Disease. Front. Immunol. 10:334.
doi: 10.3389/fimmu.2019.00334
Copyright © 2019 Soares, Azevedo, Ferreira, Bucar, Ribeiro, Vieira, Pereira, Ribeiro,
Ligeiro, Alho, Soares, Camacho, Martins, Lourenço, Moreno, Ritz and Lacerda.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | www.frontiersin.org 15 March 2019 | Volume 10 | Article 334
